1-20 of 28
Joel Morris
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

HTS384 NCI60: The Next Phase of the NCI60 Screen

Mark W. Kunkel, Nathan P. Coussens, Joel Morris, Ronald C. Taylor, Thomas S. Dexheimer, Eric M. Jones, James H. Doroshow, Beverly A. Teicher
Journal: Cancer Research
Cancer Res (2024) 84 (15): 2403–2416.
https://doi.org/10.1158/0008-5472.CAN-23-3031
Published: 01 August 2024
View article titled, HTS384 NCI60: The Next Phase of the NCI60 Screen
Open the PDF for HTS384 NCI60: The Next Phase of the NCI60 Screen in another window
Includes: Supplementary data
Journal Articles

Abstract 2665: Biochemical inhibition profiles of 370 wild type human kinases provide a basis for selecting alternative combinations of EGFR and VEGFR inhibitors

Nathan P. Coussens, Thomas S. Dexheimer, Thomas Silvers, Shannon Uzelac, Kyle Georgius, John Carter, Tia Shearer, Rekha Rao, Karen Gray, Apurva K. Srivastava, Robert J. Kinders, Yvonne A. Evrard, Melinda G. Hollingshead, Joel Morris, Jeffrey A. Moscow, Ralph E. Parchment, Beverly A. Teicher, James H. Doroshow
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 2665.
https://doi.org/10.1158/1538-7445.AM2023-2665
Published: 04 April 2023
View article titled, Abstract 2665: Biochemical inhibition profiles of 370 wild type human kinases provide a basis for selecting alternative combinations of EGFR and VEGFR inhibitors
Journal Articles

Abstract 2025: Phosphoproteomic profiling following MAP3K1 kinase inhibition identifies NPM1 as a novel substrate

Lidia Boghean, Sarbjit Singh, Kiran Mangalaparthi, Surendra K. Shukla, Smitha Kizhake, Amritha Kizhake, Donn Wishka, Jayapal Reddy Mallareddy, Joel Morris, Paul Grothaus, Pankaj K. Singh, Akhilesh Pandey, Amarnath Natarajan
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 2025.
https://doi.org/10.1158/1538-7445.AM2023-2025
Published: 04 April 2023
View article titled, Abstract 2025: Phosphoproteomic profiling following MAP3K1 kinase inhibition identifies NPM1 as a novel substrate
Journal Articles

Abstract 4884: Targeted investigational oncology agents (IOA) in the NCI60: a phenotypic systems-based resource

Joel Morris, Mark W. Kunkel, Stephen L. White, Donn G. Wishka, Omar D. Lopez, Lori Bowles, Penny Sellers, Patricia Ramsey, Julie Grams, Tiffany Rohrer, Karen Martin, Thomas Dexheimer, Dmitriy Sonkin, John D. Williams, Jerry M. Collins, James H. Doroshow, Beverly A. Teicher
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 4884.
https://doi.org/10.1158/1538-7445.AM2023-4884
Published: 04 April 2023
View article titled, Abstract 4884: Targeted investigational oncology agents (IOA) in the NCI60: a phenotypic systems-based resource
Journal Articles

Abstract 4555: Aryl-hydrocarbon receptor inhibitors in combination with anticancer agents, especially proteasome pathway inhibitors, in a complex spheroid screen using patient-derived cell lines can result in greater-than additive cytotoxicity

BEVERLY A. TEICHER, Jeffrey A. Moscow, Joel Morris, James H. Doroshow, Thomas S. Dexheimer, Nathan P. Coussens, Thomas Silvers, Rene Delosh, Zahra Davoudi, Russel Reinhart, Chad Ogle, Eric Jones
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 4555.
https://doi.org/10.1158/1538-7445.AM2023-4555
Published: 04 April 2023
View article titled, Abstract 4555: Aryl-hydrocarbon receptor inhibitors in combination with anticancer agents, especially proteasome pathway inhibitors, in a complex spheroid screen using patient-derived cell lines can result in greater-than additive cytotoxicity
Journal Articles

Abstract 1055: Screens of targeted agents combined with the ubiquitin activating enzyme inhibitor TAK-243 or the pan-Akt inhibitor ipatasertib identified combinations that are effective in patient-derived complex spheroids

Nathan P. Coussens, John J. Wright, Ralph E. Parchment, René Delosh, Julie Laudeman, Russell Reinhart, Chad Ogle, Thomas Silvers, Thomas S. Dexheimer, Joel Morris, James H. Doroshow, Beverly A. Teicher
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 1055.
https://doi.org/10.1158/1538-7445.AM2022-1055
Published: 15 June 2022
View article titled, Abstract 1055: Screens of targeted agents combined with the ubiquitin activating enzyme inhibitor TAK-243 or the pan-Akt inhibitor ipatasertib identified combinations that are effective in patient-derived complex spheroids
Journal Articles

Abstract 1054: RAS-pathway inhibitors (Sotorasib, MRTX-1257, TNO-155, BI-3406) in a Complex Spheroid Combination Screen with PDMR Cell Lines

Naoko Takebe, Thomas Dexheimer, Thomas Silvers, Rene Delosh, Julie Laudeman, Siddhartha Paul, Russell Reinhardt, Chad Ogle, Joel Morris, Nathan Coussens, James H. Doroshow, Beverly A. Teicher
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 1054.
https://doi.org/10.1158/1538-7445.AM2022-1054
Published: 15 June 2022
View article titled, Abstract 1054: RAS-pathway inhibitors (Sotorasib, MRTX-1257, TNO-155, BI-3406) in a Complex Spheroid Combination Screen with PDMR Cell Lines
Journal Articles

Abstract 1881: Drug combination screening of Ipatasertib and Abemaciclib with other targeted agents in complex multicellular tumor spheroids from the NCI-60 and the National Cancer Institute’s Patient-Derived Models Repository

Thomas Steven Dexheimer, Thomas Silvers, Rene Delosh, Julie Laudeman, Russell Reinhart, Chad Ogle, Siddhartha Paul, Nathan P. Coussens, Ralph E. Parchment, Joel Morris, John Wright, Naoko Takebe, Beverly A. Teicher, James H. Doroshow
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 1881.
https://doi.org/10.1158/1538-7445.AM2022-1881
Published: 15 June 2022
View article titled, Abstract 1881: Drug combination screening of Ipatasertib and Abemaciclib with other targeted agents in complex multicellular tumor spheroids from the NCI-60 and the National Cancer Institute’s Patient-Derived Models Repository
Journal Articles

Abstract 1072: Combination screening of DNA damaging agents temozolomide and trabectedin with inhibitors of DNA repair using a complex spheroid model with a panel of patient-derived and established tumor cell lines

Nathan P. Coussens, Ralph E. Parchment, Jeffrey A. Moscow, L. Austin Doyle, René Delosh, Julie Laudeman, Russell Reinhart, Chad Ogle, Thomas Silvers, Thomas S. Dexheimer, Joel Morris, Beverly A. Teicher, James H. Doroshow
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1072.
https://doi.org/10.1158/1538-7445.AM2021-1072
Published: 01 July 2021
View article titled, Abstract 1072: Combination screening of DNA damaging agents temozolomide and trabectedin with inhibitors of DNA repair using a complex spheroid model with a panel of patient-derived and established tumor cell lines
Journal Articles

Abstract 1961: Preclinical development of NSC-801845, a new cytidine analog, in comparative cell culture and xenograft studies with the clinical candidates T-dCyd and aza-T-dCyd

Joel Morris, Donn Wishka, Omar Lopez, Beverly A. Teicher, Raymond Divelbiss, Suzanne Borgel, Kyle Georgius, John Carter, Howard Stotler, Jerry Collins, Melinda Hollingshead
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 1961.
https://doi.org/10.1158/1538-7445.AM2020-1961
Published: 15 August 2020
View article titled, Abstract 1961: Preclinical development of NSC-801845, a new cytidine analog, in comparative cell culture and xenograft studies with the clinical candidates T-dCyd and aza-T-dCyd
Journal Articles

Abstract 328: DNA damage inhibitors with topotecan in a complex spheroid model in PDM and established cell lines

Beverly A. Teicher, Austin Doyle, John Wright, Charles Kunos, Thomas Silvers, Rene Delosh, Julie Laudeman, Russell Reinhart, Chad Ogle, Nathan Coussens, Joel Morris, James Doroshow
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 328.
https://doi.org/10.1158/1538-7445.AM2020-328
Published: 15 August 2020
View article titled, Abstract 328: DNA damage inhibitors with topotecan in a complex spheroid model in PDM and established cell lines
Journal Articles

Abstract 3839: Comparison of thio-deoxy-cytidine (TdCyd) and aza-thio-deoxy-cytidine (Aza-TdCyd) in solid and liquid tumor cell lines and PPTC pediatric xenografts

Beverly A. Teicher, Richard B. Lock, Kathryn Evans, Peter J. Houghton, Raushan T. Kurmasheva, Richard Gorlicki, Steve Erickson, Donn Wishka, Joel Morris, Michael Difilippantonio, Jerry E. Collins, Malcolm A. Smith, James H. Doroshow
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 3839.
https://doi.org/10.1158/1538-7445.AM2019-3839
Published: 01 July 2019
View article titled, Abstract 3839: Comparison of thio-deoxy-cytidine (TdCyd) and aza-thio-deoxy-cytidine (Aza-TdCyd) in solid and liquid tumor cell lines and PPTC pediatric xenografts
Journal Articles

Abstract 4831: Small cell lung carcinoma (SCLC) cell line screen of standard of care (etoposide/carboplatin) plus a third agent

Beverly A. Teicher, Michael Selby, Thomas Silvers, Julie Laudeman, Russell Reinhart, Rene Delosh, Chad Ogle, Ralph Parchment, Julia Krushkal, Dmitriy Sonkin, Joel Morris, Mark Kunkel, David Evans
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 4831.
https://doi.org/10.1158/1538-7445.AM2017-4831
Published: 01 July 2017
View article titled, Abstract 4831: Small cell lung carcinoma (SCLC) cell line screen of standard of care (etoposide/carboplatin) plus a third agent
Journal Articles

Abstract 348: Comparison of the response of the NCI60 NSCLC panel with the response of patient-derived NSCLC lines to approved and investigational agents

Beverly A. Teicher, David Evans, Thomas Silvers, Michael Selby, Rene Delosh, Julie Laudeman, Chad Ogle, Russell Reinhart, Joel Morris, Gurmeet Kaur, James Doroshow
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 348.
https://doi.org/10.1158/1538-7445.AM2017-348
Published: 01 July 2017
View article titled, Abstract 348: Comparison of the response of the NCI60 NSCLC panel with the response of patient-derived NSCLC lines to approved and investigational agents
Journal Articles

Abstract 5406: Osteosarcoma cell lines response to approved and investigational anticancer agents and statins along with gene and microRNA expression

Gurmeet Kaur, Eric Polley, Joel Morris, Thomas Silvers, Michael Selby, Rene Delosh, Julie Laudeman, Chad Ogle, Russell Reinhart, Anne Monks, Annamaria Rapisarda, David Evans, Beverly A. Teicher
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 5406.
https://doi.org/10.1158/1538-7445.AM2015-5406
Published: 01 August 2015
View article titled, Abstract 5406: Osteosarcoma cell lines response to approved and investigational anticancer agents and statins along with gene and microRNA expression
Journal Articles

Abstract 3749: Uses and update for CellMiner, a tool for access to and comparison of molecular data and pharmacological response for the NCI-60

William C. Reinhold, Margot Sunshine, Sudir Varma, Vinodh Rajapakse, James Doroshow, Joel Morris, Yves Pmmier
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 3749.
https://doi.org/10.1158/1538-7445.AM2015-3749
Published: 01 August 2015
View article titled, Abstract 3749: Uses and update for CellMiner, a tool for access to and comparison of molecular data and pharmacological response for the NCI-60
Journal Articles

ATR Inhibitors VE-821 and VX-970 Sensitize Cancer Cells to Topoisomerase I Inhibitors by Disabling DNA Replication Initiation and Fork Elongation Responses

Rozenn Jossé, Scott E. Martin, Rajarshi Guha, Pinar Ormanoglu, Thomas D. Pfister, Philip M. Reaper, Christopher S. Barnes, Julie Jones, Peter Charlton, John R. Pollard, Joel Morris, James H. Doroshow, Yves Pommier
Journal: Cancer Research
Cancer Res (2014) 74 (23): 6968–6979.
https://doi.org/10.1158/0008-5472.CAN-13-3369
Published: 30 November 2014
View article titled, ATR Inhibitors VE-821 and VX-970 Sensitize Cancer Cells to Topoisomerase I Inhibitors by Disabling DNA Replication Initiation and Fork Elongation Responses
Open the PDF for ATR Inhibitors VE-821 and VX-970 Sensitize Cancer Cells to Topoisomerase I Inhibitors by Disabling DNA Replication Initiation and Fork Elongation Responses in another window
Includes: Supplementary data
Journal Articles

Abstract 5327: Using CellMiner for gene expression, DNA copy number, microRNA transcript levels, variant status, drug activity, and their integration for systems pharmacology for the NCI-60

William C. Reinhold, Margot Sunshine, Sudir Varma, Joel Morris, Kurt Kohn, James Doroshow, Yves Pommier
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 5327.
https://doi.org/10.1158/1538-7445.AM2014-5327
Published: 01 October 2014
View article titled, Abstract 5327: Using CellMiner for gene expression, DNA copy number, microRNA transcript levels, variant status, drug activity, and their integration for systems pharmacology for the NCI-60
Journal Articles

Abstract 5450: Screening more than 60 human SCLC lines with approved and investigational agents indicates complex patterns of response: Identification of HSP90 and HDACs as potential targets

David M. Evans, Rene Delosh, Julie Laudeman, Chad Ogle, Russell Reinhart, Michael Selby, Thomas Silvers, John Connelly, Anne Monks, Eric Polley, Gurmeet Kaur, Joel Morris, Beverly Teicher
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 5450.
https://doi.org/10.1158/1538-7445.AM2014-5450
Published: 01 October 2014
View article titled, Abstract 5450: Screening more than 60 human SCLC lines with approved and investigational agents indicates complex patterns of response: Identification of HSP90 and HDACs as potential targets
Journal Articles

Abstract 5508: Bromodomain and hegdehog pathway targets in small cell lung cancer

Gurmeet Kaur, Russell A. Reinhart, Anne Monks, David Evans, Joel Morris, Beverly A. Teicher
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 5508.
https://doi.org/10.1158/1538-7445.AM2014-5508
Published: 01 October 2014
View article titled, Abstract 5508: Bromodomain and hegdehog pathway targets in small cell lung cancer